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An important step in in vitro test system 
development is the choice of an adequate cell 
line which depends on the intended applica-
tion of the assay. In a recent study, Tuuli 
Karhu and colleagues from Helsinki Univer-
sity compared a set of cell lines for their sus-
ceptibility towards eight GATA4 targeting 
compounds (Karhu et al., 2018). GATA4 is a 
transcription factor involved in cardiac devel-
opment (Gupta et al., 2013; Kikuchi et al., 
2010; Rysä et al., 2010; Pikkarainen et al., 
2004). The goal of the study was to identify 
which cell line allows the most sensitive cy-
totoxicity screening of these compounds. The 
tested cell lines included the myoblast cell 
line H9c2 established from rat myocardium; 
primary neonatal rat cardiac fibroblasts; 
mouse embryonic fibroblasts; mouse embry-
onic stem cells (mECSs), mouse embryonic 
stem cell derivatives from day 5 embryoid 
bodies; induced pluripotent human stem cells 
(hiPSC); and hiPSC-derived cardiomyocytes. 
The most susceptible cell lines towards the set 
of test compounds were hiPSC and mESC, 
while cardiomyocytes, fibroblasts and H9c2 
cells were most resistant (Karhu et al., 2018). 
Of course screening for the most sensitive cell 
line does not guarantee that the test cells will 
be most relevant for the human in vivo situa-
tion. However, if one is interested in a cyto-
toxicity screening system with the highest 
sensitivity, the recommendation of the au-
thors to further use hiPSC seems reasonable. 
In recent years, the development of stem 
cell based test systems has been a major focus 
of research (Leist et al., 2017; Godoy et al., 
2013; Krug et al., 2013). The most frequently 
applied strategy is to expose stem cells to test 
compounds, when they differentiate to more 
mature cell types (Shinde et al., 2017; Pal-
locca et al., 2016). 
This approach has been used for develop-
mental neurotoxicity (Waldmann et al., 2014; 
Meganathan et al., 2015; Weng et al., 2014; 
Rempel et al., 2015) and for cardiotoxicity 
(Chaudhari et al., 2016a,b; Sampaio et al., 
2016) testing. While tests that analyze the in-
fluence of compounds on the differentiation 
process are already successfully applied, it 
still remains a challenge to generate mature 
cell types, e.g. hepatocytes that closely resem-
ble the primary cells in an adult organ (Godoy 
et al., 2016, 2018). Although much progress 
has been achieved in stem cell based test sys-
tem development, systematic analysis of hu-
man in vivo relevance still remains a major 
challenge. 
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